When the drugs don’t work: treatment-resistant schizophrenia, serotonin and serendipity-Reference-Cited by-同舟云学术

When the drugs don’t work: treatment-resistant schizophrenia, serotonin and serendipity

Published:2017-11-02 Issue:1 Volume:8 Page:63-70
ISSN:2045-1253
Container-title:Therapeutic Advances in Psychopharmacology
language:en
Short-container-title:Therapeutic Advances in Psychopharmacology

Author:

Lowe Penelope¹,Krivoy Amir²,Porffy Lilla³,Henriksdottir Erna⁴,Eromona Whiskey⁵,Shergill Sukhwinder S.⁵

Affiliation:

1. National Psychosis Service, South London and Maudsley NHS Foundation Trust, UK

2. Psychosis Studies Department, Institute of Psychiatry, Psychology and Neuroscience, 16 De Crespigny Park, London, SE5 8AF, UK

3. Institute of Psychiatry, Psychology and Neuroscience, King’s College London, UK

4. National Psychosis Service, South London and Maudsley NHS Foundation Trust, UK. University of Iceland, Iceland

5. National Psychosis Service, South London and Maudsley NHS Foundation Trust, UK. Institute of Psychiatry, Psychology and Neuroscience, King’s College London, UK

Abstract

Treatment-resistant schizophrenia is a serious clinical problem. We adopt a systems-level approach positing a greater role for cognitive control mechanisms in the development of psychotic symptoms and illustrate the clinical application of this via a case report of treatment-resistant patients treated successfully with adjunct pro-cognitive serotonergic medication.

Publisher

SAGE Publications

Subject

Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Psychology (miscellaneous)

Link

http://journals.sagepub.com/doi/pdf/10.1177/2045125317737003

Reference25 articles.

1. Clozapine for the Treatment-Resistant Schizophrenic

2. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses

3. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia

4. Profiling cognitive impairment in treatment-resistant schizophrenia patients

5. Symptomatic remission and neurocognitive functioning in patients with schizophrenia

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alterations of serum neuropeptide levels and their relationship to cognitive impairment and psychopathology in male patients with chronic schizophrenia;Schizophrenia;2024-01-03

2. MicroRNAs as potential biomarkers for diagnosis of schizophrenia and influence of antipsychotic treatment;Neural Regeneration Research;2023-11-08

3. Dual orexin/hypocretin receptor antagonism attenuates NMDA receptor hypofunction-induced attentional impairments in a rat model of schizophrenia;Behavioural Brain Research;2023-07

4. Treatment of Depression with Vortioxetine and Second Generation Antipsychotics During the Period of Remission Formation in Schizophrenia (Interim Data Analysis);Consortium Psychiatricum;2023-03-31

5. Abnormal resting-state functional connectivity underlies cognitive and clinical symptoms in patients with schizophrenia;Frontiers in Human Neuroscience;2023-02-15